Sign In
Buy BSEM
$4.14
-0.0290 (-0.696%)
At Close: Jun 03, 2026
BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair
07:00am, Monday, 23'rd Mar 2026
SEC-Qualified Financial Expert and Life Sciences Veteran Brings 29 Years of Accounting Leadership to the Board Pompano Beach, Fla, March 23, 2026 – PRISM MediaWire (Press Release Service – Press R
BioStem Technologies to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 24, 2026
04:06pm, Wednesday, 11'th Mar 2026
Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., March 11, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc.
Head to Head Analysis: Cardiff Oncology (NASDAQ:CRDF) and BioStem Technologies (OTCMKTS:BSEM)
04:26am, Wednesday, 11'th Mar 2026
BioStem Technologies (OTCMKTS:BSEM - Get Free Report) and Cardiff Oncology (NASDAQ: CRDF - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast t
BioStem Technologies to Present at the 46th Annual TD Cowen Healthcare Conference
07:01am, Friday, 20'th Feb 2026
POMPANO BEACH, Fla., February 20, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc.
BioStem Technologies to Present at the 46th Annual TD Cowen Healthcare Conference
07:00am, Friday, 20'th Feb 2026
POMPANO BEACH, Fla., Feb. 20, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal t
BioStem Technologies Highlights Alignment with FDA's Openness to Bayesian Statistical Approaches in Clinical Research
04:09pm, Tuesday, 03'rd Feb 2026
POMPANO BEACH, Fla., February 3, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the de
BioStem Technologies Highlights Alignment with FDA's Openness to Bayesian Statistical Approaches in Clinical Research
04:05pm, Tuesday, 03'rd Feb 2026
POMPANO BEACH, Fla., Feb. 03, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal t
BioStem Technologies, Inc. (BSEM) M&A Call Transcript
10:14am, Thursday, 22'nd Jan 2026
BioStem Technologies, Inc. (BSEM) M&A Call Transcript
BioTissue Deepens Commitment to Ocular Market Leadership MIAMI, Jan. 21, 2026 /PRNewswire/ -- BioTissue Holdings, Inc, a leader in harnessing the unique properties of human birth tissue to facilitate
Accelerates expansion of BioStem's commercial organization through integration of an experienced national sales force Expands access to major GPO networks, strengthening BioStem's position across hosp
Accelerates expansion of BioStem's commercial organization through integration of an experienced national sales force Expands access to major GPO networks, strengthening BioStem's position across hosp
BioStem Technologies Comments on Withdrawal of CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes
04:05pm, Wednesday, 07'th Jan 2026
Decision ensures continued patient access to VENDAJE® and VENDAJE AC® POMPANO BEACH, Fla., Jan. 07, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Techn
BioStem Technologies (OTCMKTS:BSEM) Shares Down 0.8% – Time to Sell?
02:55am, Tuesday, 30'th Dec 2025
BioStem Technologies, Inc. (OTCMKTS:BSEM - Get Free Report)'s stock price was down 0.8% during mid-day trading on Monday. The stock traded as low as $3.72 and last traded at $3.84. Approximately 72,84
POMPANO BEACH, FL, December 18, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc.
BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes
